Prof Carlos Zubaran Jr
MD, MHM, PhD, FRANZCP
Professor Carlos Zubaran Jr is a Fellow of the Royal Australian and New Zealand College of Psychiatrists (FRANZCP), and an Accredited Member of the Faculty of Adult Psychiatry and the Faculty of Addiction Psychiatry. Prof Zubaran also holds conjoint professorial appointments with the Schools of Medicine at Western Sydney University and the School of Medicine at Notre Dame University in Sydney.
Professor Zubaran graduated in 1992 at UFRGS Faculty of Medicine, a centenarian higher education institution in Southern Brazil. After having obtained his specialty in Psychiatry and a PhD in Biological Sciences, Professor Zubaran completed research programs at the Institute of Psychiatry and Maudsley Hospital in London (1996-1998), as well as postdoctoral programs (2000-2002) at Columbia University and New York State Psychiatric Institute and at the International Center for Mental Health at Elmhurst Hospital in New York City. Professor Zubaran also completed a research sabbatical term at the Epidemiology and Prevention Research Group (EPRG), Department of Psychiatry at Washington University in St. Louis School of Medicine (2008). He also obtained a masterâ€™s degree in Health Management from the University of New South Wales (2011).
Professor Zubaran was the recipient of the World Psychiatric Association International Fellowship Award (1996), the US National Institute on Drug Abuse Distinguished International Scientist Award (2009), and the Eric Roger Wroclawski Award (2013). In 2014 Professor Zubaran delivered the Elysio de Moura Invitational Oration at Coimbra University, Portugal.
Professor Carlos Zubaran has authored more than one hundred publications including scientific manuscripts, research abstracts, essays and book chapters. Professor Zubaran has secured research funding and coordinated research projects in the fields of substance use, transcultural psychiatry, and perinatal mental health, as well as executed a randomized controlled trial (RCT) designed to assess adherence to treatment among people living with HIV.